Head-to-head evidence
albuterol / budesonide vs Lodotra
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor · full Asthma pipeline
albuterol / budesonide · Airsupra
Marketed by AstraZeneca
NCT03769090 · Phase 3 · completed
Participants were randomized and quadruple-blinded across two budesonide/albuterol groups and an active albuterol comparator, with 3,132 randomized participants. The primary clinical endpoint was met for both doses: severe exacerbations occurred in 207/1,013 versus 266/1,014 participants for high-dose treatment (hazard ratio 0.733, p<0.001) and 241/1,054 versus 276/1,056 for low-dose treatment (hazard ratio 0.835, p=0.041).
Next expected readout: February 2027 · NCT06422689 (registry estimate)
Lodotra · Rayos
Marketed by Amgen
NCT00686335 · Phase 2 · completed
This was a single-group, sequential (not randomized) study with no blinding and no true parallel control arm - patients simply switched from morning to evening dosing of the same drug class, and only 7 of 12 enrolled patients completed both periods for the efficacy analysis. The sponsor describes the study as exploratory with descriptive-only analysis and no statistical hypothesis testing, so despite numbers suggesting fewer nighttime awakenings with the evening formulation, this small, unblinded, uncontrolled design cannot serve as strong evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol / budesonide's landscape · Lodotra's landscape